Benjamin Levy

Also affiliated with Sidney Kimmel Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results”.

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Nature Medicine(2023)10.1038/s41591-023-02598-9

N/A

3.7DataRank · unranked

151 citations

Cheryl Ho, Garth Nicholas, Rosalyn A. Juergens, Adrian G. Sacher, Andrea S. Fung +15 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0.769DataRank · unranked

168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Persistent mutation burden drives sustained anti-tumor immune responses

Nature Medicine(2023)10.1038/s41591-022-02163-w

N/A

0.747DataRank · unranked

144 citations

Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M. Shao +16 more

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-004688

N/A

0.743DataRank · unranked

141 citations

Jenna VanLiere Canzoniero, Samuel Rosner, Guangfan Zhang, James R. White, Zineb Belcaid +22 more

Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005924

N/A

0.712DataRank · unranked

114 citations

Joseph C. Murray, Jenna VanLiere Canzoniero, Blair V. Landon, Jennifer Jackson, Susan Scott +5 more

Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1469

N/A

0.538DataRank · unranked

35 citations

Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R. White, Noushin Niknafs +28 more

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy

The Oncologist(2022)10.1093/oncolo/oyac140

N/A

0.464DataRank · unranked

21 citations

Joseph C. Murray, Kevin J. Psoter, Jiajia Zhang, Durrant Barasa, Julie R. Brahmer +14 more

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100220

N/A

0.416DataRank · unranked

15 citations

Emily Brigham, Kevin J. Psoter, Khinh Ranh Voong, Bairavi Shankar, David S. Ettinger +16 more

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade

Frontiers in Oncology(2022)10.3389/fonc.2022.945798

N/A

0.396DataRank · unranked

13 citations

Xiaoshan M. Shao, Noushin Niknafs, Archana Balan, Gavin Pereira, Kristen A. Marrone +12 more

Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.06.23.546338

N/A

0.261DataRank · unranked

3 citations

Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R. White, Noushin Niknafs +25 more

971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)

Annals of Oncology(2022)10.1016/j.annonc.2022.07.1097

N/A

0DataRank · unranked

6 citations

Benjamin Levy, H. Horinouchi, J. Yu, Elizabeth M. Grainger, P. Phuong +4 more

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

UNC Libraries(2020)10.17615/74ry-7003

N/A

0DataRank · unranked

0 citations

Editta Baldini, Pierre-Jean Souquet, Grace K. Dy, Ariel López-Chávez, Federico Cappuzzo +25 more